These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 26365516)
21. MicroRNA expression signature of castration-resistant prostate cancer: the microRNA-221/222 cluster functions as a tumour suppressor and disease progression marker. Goto Y; Kojima S; Nishikawa R; Kurozumi A; Kato M; Enokida H; Matsushita R; Yamazaki K; Ishida Y; Nakagawa M; Naya Y; Ichikawa T; Seki N Br J Cancer; 2015 Sep; 113(7):1055-65. PubMed ID: 26325107 [TBL] [Abstract][Full Text] [Related]
22. Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer. Lin HM; Mahon KL; Spielman C; Gurney H; Mallesara G; Stockler MR; Bastick P; Briscoe K; Marx G; Swarbrick A; Horvath LG Br J Cancer; 2017 Apr; 116(8):1002-1011. PubMed ID: 28278515 [TBL] [Abstract][Full Text] [Related]
23. MicroRNA expression profile of primary prostate cancer stem cells as a source of biomarkers and therapeutic targets. Rane JK; Scaravilli M; Ylipää A; Pellacani D; Mann VM; Simms MS; Nykter M; Collins AT; Visakorpi T; Maitland NJ Eur Urol; 2015 Jan; 67(1):7-10. PubMed ID: 25234358 [TBL] [Abstract][Full Text] [Related]
24. Gene expression profiling analysis of castration-resistant prostate cancer. Wang X; Wen J; Li R; Qiu G; Zhou L; Wen X Med Sci Monit; 2015 Jan; 21():205-12. PubMed ID: 25592164 [TBL] [Abstract][Full Text] [Related]
25. Bone Scan Index Is an Independent Predictor of Time to Castration-resistant Prostate Cancer in Newly Diagnosed Prostate Cancer: A Prospective Study. Zacho HD; Gade M; Mortensen JC; Bertelsen H; Boldsen SK; Barsi T; Petersen LJ Urology; 2017 Oct; 108():135-141. PubMed ID: 28760556 [TBL] [Abstract][Full Text] [Related]
26. A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer. Seisen T; Rouprêt M; Gomez F; Malouf GG; Shariat SF; Peyronnet B; Spano JP; Cancel-Tassin G; Cussenot O Cancer Treat Rev; 2016 Jul; 48():25-33. PubMed ID: 27327958 [TBL] [Abstract][Full Text] [Related]
27. The Role of Next-Generation Sequencing in Castration-Resistant Prostate Cancer Treatment. Hovelson DH; Tomlins SA Cancer J; 2016; 22(5):357-361. PubMed ID: 27749331 [TBL] [Abstract][Full Text] [Related]
28. Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer. Benidir T; Hersey K; Finelli A; Hamilton R; Joshua AM; Kulkarni G; Zlotta A; Fleshner N Urol Oncol; 2018 May; 36(5):240.e13-240.e20. PubMed ID: 29454590 [TBL] [Abstract][Full Text] [Related]
29. Predictors for progression of metastatic prostate cancer to castration-resistant prostate cancer in Indians. Sureka SK; Maheshwari R; Agnihotri S; Mitash N; Ahmad S; Mandhani A Indian J Med Res; 2016 May; 143(Supplement):S68-S73. PubMed ID: 27748280 [TBL] [Abstract][Full Text] [Related]
30. The predictive value of ERG protein expression for development of castration-resistant prostate cancer in hormone-naïve advanced prostate cancer treated with primary androgen deprivation therapy. Berg KD; Røder MA; Thomsen FB; Vainer B; Gerds TA; Brasso K; Iversen P Prostate; 2015 Oct; 75(14):1499-509. PubMed ID: 26053696 [TBL] [Abstract][Full Text] [Related]
31. A Phase 2 Randomized Controlled Trial of Personalized Peptide Vaccine Immunotherapy with Low-dose Dexamethasone Versus Dexamethasone Alone in Chemotherapy-naive Castration-resistant Prostate Cancer. Yoshimura K; Minami T; Nozawa M; Kimura T; Egawa S; Fujimoto H; Yamada A; Itoh K; Uemura H Eur Urol; 2016 Jul; 70(1):35-41. PubMed ID: 26782346 [TBL] [Abstract][Full Text] [Related]
32. MLL translocation in two castration-resistant prostate cancer patients. Chowdry RP; Ledet E; Ranasinghe L; Sartor AO Can J Urol; 2016 Oct; 23(5):8483-8486. PubMed ID: 27705736 [TBL] [Abstract][Full Text] [Related]
33. Development of Castration Resistant Prostate Cancer can be Predicted by a DNA Hypermethylation Profile. Angulo JC; Andrés G; Ashour N; Sánchez-Chapado M; López JI; Ropero S J Urol; 2016 Mar; 195(3):619-26. PubMed ID: 26551297 [TBL] [Abstract][Full Text] [Related]
34. PDLIM2 suppression efficiently reduces tumor growth and invasiveness of human castration-resistant prostate cancer-like cells. Kang M; Lee KH; Lee HS; Park YH; Jeong CW; Ku JH; Kim HH; Kwak C Prostate; 2016 Feb; 76(3):273-85. PubMed ID: 26499308 [TBL] [Abstract][Full Text] [Related]
35. Dual strands of pre-miR‑150 (miR‑150‑5p and miR‑150‑3p) act as antitumor miRNAs targeting SPOCK1 in naïve and castration-resistant prostate cancer. Okato A; Arai T; Kojima S; Koshizuka K; Osako Y; Idichi T; Kurozumi A; Goto Y; Kato M; Naya Y; Ichikawa T; Seki N Int J Oncol; 2017 Jul; 51(1):245-256. PubMed ID: 28534948 [TBL] [Abstract][Full Text] [Related]
36. The prognostic significance of OCT4 expression in patients with prostate cancer. Kosaka T; Mikami S; Yoshimine S; Miyazaki Y; Daimon T; Kikuchi E; Miyajima A; Oya M Hum Pathol; 2016 May; 51():1-8. PubMed ID: 27067776 [TBL] [Abstract][Full Text] [Related]
37. A hnRNP K⁻AR-Related Signature Reflects Progression toward Castration-Resistant Prostate Cancer. Capaia M; Granata I; Guarracino M; Petretto A; Inglese E; Cattrini C; Ferrari N; Boccardo F; Barboro P Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29966326 [TBL] [Abstract][Full Text] [Related]
38. Nucleoporin 62 and Ca(2+)/calmodulin dependent kinase kinase 2 regulate androgen receptor activity in castrate resistant prostate cancer cells. Karacosta LG; Kuroski LA; Hofmann WA; Azabdaftari G; Mastri M; Gocher AM; Dai S; Hoste AJ; Edelman AM Prostate; 2016 Feb; 76(3):294-306. PubMed ID: 26552607 [TBL] [Abstract][Full Text] [Related]
39. High expression of TROP2 characterizes different cell subpopulations in androgen-sensitive and androgen-independent prostate cancer cells. Xie J; Mølck C; Paquet-Fifield S; Butler L; ; Sloan E; Ventura S; Hollande F Oncotarget; 2016 Jul; 7(28):44492-44504. PubMed ID: 27283984 [TBL] [Abstract][Full Text] [Related]
40. MiR-4638-5p inhibits castration resistance of prostate cancer through repressing Kidins220 expression and PI3K/AKT pathway activity. Wang Y; Shao N; Mao X; Zhu M; Fan W; Shen Z; Xiao R; Wang C; Bao W; Xu X; Yang C; Dong J; Yu D; Wu Y; Zhu C; Wen L; Lu X; Lu YJ; Feng N Oncotarget; 2016 Jul; 7(30):47444-47464. PubMed ID: 27329728 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]